Tenax Therapeutics (NASDAQ:TENX) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Tenax Therapeutics (NASDAQ:TENX) posted its earnings results on Thursday. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.04, FiscalAI reports.

Tenax Therapeutics Price Performance

Shares of TENX stock traded up $0.06 during trading hours on Friday, hitting $1.69. The stock had a trading volume of 783,328 shares, compared to its average volume of 2,029,769. The firm has a market capitalization of $63.24 million, a PE ratio of -1.22 and a beta of 0.99. Tenax Therapeutics has a twelve month low of $1.31 and a twelve month high of $19.40. The stock’s 50 day moving average is $1.81 and its 200 day moving average is $9.74.

Insider Activity at Tenax Therapeutics

In other Tenax Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 900,000 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were acquired at an average cost of $1.78 per share, with a total value of $1,602,000.00. Following the acquisition, the insider directly owned 6,524,151 shares of the company’s stock, valued at $11,612,988.78. The trade was a 16.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last 90 days, insiders have acquired 3,682,899 shares of company stock valued at $6,388,279. Insiders own 10.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on TENX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tenax Therapeutics in a research note on Thursday, September 10th. Roth Capital set a $5.00 price objective on shares of Tenax Therapeutics in a research report on Monday, August 10th. Wall Street Zen upgraded shares of Tenax Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Evercore cut shares of Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price for the company. in a report on Tuesday, August 11th. Finally, William Blair downgraded shares of Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.00.

Key Stories Impacting Tenax Therapeutics

Here are the key news stories impacting Tenax Therapeutics this week:

• Positive Sentiment: Tenax reported a third-quarter loss of $0.31 per share, narrower than analysts’ expected $0.35 loss. The company also said analyses of its LEVEL trial informed a predictive-enrichment strategy for the amended LEVEL-2 protocol, and that it has been granted a Type C meeting with the FDA. Tenax reports third-quarter results and corporate update
• Neutral Sentiment: The class action’s lead-plaintiff deadline is December 28, 2026. The court has not established that the allegations are true. Johnson Fistel investor alert
• Negative Sentiment: Investors’ attention is focused on a securities class action covering purchases from November 13, 2023, through August 7, 2026. The complaint alleges Tenax and certain executives made misleading statements about TNX-103’s clinical prospects; one notice says the company raised $134 million before its Phase 3 LEVEL trial missed its primary endpoint. The litigation creates uncertainty and could add legal costs, although the claims remain allegations. TENX shareholder alert and lawsuit allegations

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.